Search companies on Owler
Advanced Search
Latest news
Newsfeed
My followed companies
Followed Companies

Lipocine

Lipocine is a biopharmaceutical company that researches, develops and commercializes drugs for the treatment of metabolic and endocrine disorders. Read more

21 Followers on Owler
21 Followers on Owler
21 Followers on Owler
21 Followers on Owler

Lipocine

Lipocine is a biopharmaceutical company that researches, develops and commercializes drugs for the treatment of metabolic and endocrine disorders. Read more

Mahesh V. Patel's photo - Chairman & CEO of Lipocine

Chairman & CEO

Mahesh V. Patel

CEO Approval Rating

90/100

Founded:

1997

Status:

PublicIndependent CompanyNASDAQLPCN

SIC Code:

2834 NAICS listing »

2836 NAICS listing »

Website:

Annual Revenue
Employees
Sector

- -
Headquarters

LIPOCINE TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

The top 10 competitors in Lipocine's competitive set are Repros Therapeutics, Antares Pharma, AMAG, Evofem, PregLem S.A., Owen Mumford, Akebia Therapeutics, Inc., Duoject, American Regent and Pharmacosmos A/S. Together they have raised over 461.9M between their estimated 2.7K employees. Lipocine has 10 employees and is ranked 10th among it's top 10 competitors. The top 10 competitors average 228.

Repros Therapeutics is a top competitor of Lipocine. Repros Therapeutics is a Private company that was founded in 1987 in The Woodlands, Texas. Repros Therapeutics operates in the Biotechnology industry. Compared to Lipocine, Repros Therapeutics has 14 more employees.

Antares Pharma is seen as one of Lipocine's biggest rivals. Antares Pharma was founded in 1978, and is headquartered in Ewing, New Jersey. Antares Pharma operates in the Pharmaceuticals industry. Antares Pharma generates $254.9M more revenue vs. Lipocine.

AMAG is seen as one of Lipocine's top competitors. AMAG was founded in Waltham, Massachusetts} in 1981. AMAG competes in the Pharmaceuticals industry. Compared to Lipocine, AMAG generates $304.1M more revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Evofem a competitor of Lipocine?

I don't know

Trending News for Lipocine and Lipocine's Competitors

May 8, 2021

Portland Press Herald

EU agrees to potential 1.8 billion-dose purchase of Pfizer vaccine

The bloc is looking for ways to provide booster shots and expand vaccination drives to include childr... See more »

Today 2:28 PM

Channel News Asia

EU has not yet ordered more AstraZeneca vaccines: Internal market commissioner

PARIS: The European Union has not yet made any new orders for AstraZeneca vaccines beyond June when t... See more »

May 7, 2021

MarketScreener

Evofem Biosciences : Reports First Quarter 2021 Financial Results and Provides Corporate Update

(marketscreener.com) Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Cor... See more »

Lipocine Quarterly and Annual Revenue

Coming soon for Lipocine!

Annual Revenue

$ < 1M

Lipocine's revenue is the ranked lowest among it's top 10 competitors. The top 10 competitors average 374M.

Lipocine Acquisitions

No recent acquisitions found related to Lipocine

Lipocine Funding History

Since Lipocine was founded in 1997, it has participated in 3 rounds of funding. In total Lipocine has raised $76.2M. Lipocine's last funding round was on Apr 2020 for a total of $150.0K

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt - PPP (CARES Act)
Apr 2020
$150K - $350K
IPO
Aug 2013
$38M

Private Placement
Jul 2013
$38M
-

Total Funding: $76.2M

Since Lipocine was founded in 1997, it has participated in 3 rounds of funding. In total Lipocine has raised $76.2M. Lipocine's last funding round was on Apr 2020 for a total of $150.0K

Lipocine Investments

No recent investments found related to Lipocine

Lipocine News

December 30, 2020RTTNews

Lipocine Enrolling Patients Into Open Label Extension To LPCN 1144 Phase 2 LiFT Study

Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company, said Wednesday it is enrolling pati... See more »
December 29, 2020MarketScreener

Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics

(marketscreener.com) SALT LAKE CITY, Dec. 29, 2020 /PRNewswire/ -- Lipocine Inc. , a clinical-stage b... See more »
December 9, 2020RTTNews

FDA Finally Gives Tentative Approval To Lipocine's Oral Testosterone Replacement Therapy

Lipocine Inc.'s (LPCN) Tlando, an oral testosterone product, which failed to get the FDA nod thrice, ... See more »
December 4, 2020MarketScreener

Lipocine Provides New Regulatory Update on TLANDO

(marketscreener.com) SALT LAKE CITY, Dec. 4, 2020 /PRNewswire/ -- Lipocine Inc. , a clinical-stage bi... See more »
November 10, 2020NewsOk

3Q Earnings Snapshot

SALT LAKE CITY (AP) _ Lipocine Inc. (LPCN) on Tuesday reported a loss of $4.3 million in its third qu... See more »
November 10, 2020BioSpace

Lipocine Announces Third Quarter 2020 Financial and Operational Results

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and end... See more »
September 21, 2020Seeking Alpha

Lipocine announces completion of enrollment in the LPCN 1144 lift study

See more »

Lipocine Press Releases

January 14, 2021PR Newswire

Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications

SALT LAKE CITY, Jan. 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharm... See more »
January 4, 2021PR Newswire

Lipocine to Present at the H.C. Wainwright BioConnect 2021 Conference

SALT LAKE CITY, Jan. 4, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharma... See more »
December 9, 2020centralcharts

Lipocine Announces Tentative Approval of TLANDO

Lipocine Announces Tentative Approval of TLANDO PR Newswire SALT LAKE CITY, Dec. 8, 2020 SALT LAKE CI... See more »
November 6, 2020PR Newswire

Lipocine Provides Regulatory Update on TLANDO

SALT LAKE CITY, Nov. 6, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharma... See more »
October 14, 2020PR Newswire

Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America

SALT LAKE CITY, Oct. 14, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharm... See more »
July 13, 2020PR Newswire

Lipocine Regains Complinace With Nasdaq Minimum Bid Price Requirement

SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharm... See more »
May 15, 2020PR Newswire

Lipocine Announces Presentations on TLANDO at AUA Virtual Experience 2020

SALT LAKE CITY, May 15, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharma... See more »

Social Media

Lipocine Headquarters

675 Arapeen Drive Suite 202

Salt Lake City, Utah84108

801-994-7383

Driving Directions »

Trending Companies

Lipocine Summary

ABOUT

Overview

Lipocine is a biopharmaceutical company that researches, develops and commercializes drugs for the treatment of metabolic and endocrine disorders. Lipocine was founded in 1997. Lipocine's headquarters is located in Salt Lake City, Utah, USA 84108. It ...

CEO

Lipocine's Chairman & CEO, Mahesh V. Patel, currently has an approval rating of 90%. Lipocine's primary competitors are Repros Therapeutics, Antares Pharma & AMAG.

Website

lipocine.com

Frequently Asked Questions about Lipocine

  1. When was Lipocine founded?

    Lipocine was founded in 1997

  2. Who is Lipocine's CEO?

    Lipocine's CEO is Mahesh V. Patel

  3. How much revenue does Lipocine generate?

    Lipocine generates $ < 1M in revenue

  4. How much funding does Lipocine have?

    Lipocine has historically raised $76.2M in funding

  1. Where is Lipocine's headquarters?

    Lipocine's headquarters is in Salt Lake City Utah, USA

  2. How many employees does Lipocine have?

    Lipocine has 10 employees

  3. Who are Lipocine's competitors?

    Lipocine's top competitors are Repros Therapeutics, Antares Pharma, AMAG
Stay up-to-date with the latest news on Lipocine

© 2021 Owler, Inc.